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There is increasing evidence that proteasomes have a biological role in the extracellular alveolar space, but inﬂammation could
change their composition. We tested whether immunoproteasome protein-containing subpopulations are present in the alveolar
space of patients with lung inﬂammation evoking the acute respiratory distress syndrome (ARDS). Bronchoalveolar lavage (BAL)
supernatantsandcellpelletlysatefromARDSpatients(n = 28)andhealthysubjects(n = 10)wereanalyzedforthepresenceofim-
munoproteasome proteins (LMP2 and LMP7) and proteasome subtypes by western blot, chromatographic puriﬁcation, and 2D-
dimensional gelelectrophoresis. In all ARDS patients but not in healthy subjects LMP7 and LMP2 were observed in BAL superna-
tants. Proteasomes puriﬁed from pooled ARDS BAL supernatant showed an altered enzyme activity ratio. Chromatography
revealed a distinct pattern with 7 proteasome subtype peaks in BAL supernatant of ARDS patients that diﬀered from healthy sub-
jects. Total proteasome concentration in BAL supernatant was increased in ARDS (971ng/mL ± 1116 versus 59 ± 25; P<0.001),
and all ﬂuorogenic substrates were hydrolyzed, albeit to a lesser extent, with inhibition by epoxomicin (P = 0.0001). Thus, we
identiﬁed for the ﬁrst time immunoproteasome proteins and a distinct proteasomal subtype pattern in the alveolar space of ARDS
patients, presumably in response to inﬂammation.
1.Introduction
The proteasome is a multicatalytic enzyme complex respon-
sible for the degradation of the vast majority of intracellular
proteins [1]. Proteasomes are involved in many basic cel-
lular processes including the cell cycle, apoptosis, the stress
response, and also in the regulation of immune and inﬂam-
matory responses [2–5]. The 26S proteasome consists of a
catalytic 20S proteasome core and two 19S (cap) regulatory
complexes.
The 20S proteasome itself is a 660–700kDa [2, 6]m u l -
ticatalytic proteinase complex with a cylinder-shaped struc-
ture arranged as four axially stacked heptametrical rings
composed of seven α subunits (outer rings) and seven β sub-
units (innerrings), respectively [7].Theα type subunits have
highly conserved N-terminal extensions which were pro-
posed to have regulatory and targeting function [38]. The
proteolytic activities of the 20S proteasome are described
as trypsin, chymotrypsin, and peptidyl-glutamyl peptide hy-
drolyzing activity and are exclusively associated with the
proteasome subunits β1, β2,a n dβ5 [8, 9]. Five of the seven
β type subunits are synthesized as precursor proteins with
N-terminal propeptides that are cleaved oﬀ during 20S pro-
teasome biogenesis [13–15] that is mediated by accessory
proteins like the proteasome maturation protein (POMP)
[10].
In cells exposed to IFN-γ or TNF-α, however, the stan-
dard β subunits can be replaced by so-called immuno-sub-
units β1i (LMP2), β2i (MECL-1), and β5i (LMP7) that are
incorporated cooperatively into newly synthesized protea-
somesnamed“immunoproteasome”.Incasethatonlypartial
replacementtakesplace“intermediate-typeproteasomes”are
formed [11].2 Mediators of Inﬂammation
Table 1: Clinical characteristics of ARDS patients.
PaO2/FiO2 ratio [mmHg] 82 ±30
Positive end-expiratory pressure (PEEP) [mbar] 16 ±4
Venous admixture [%] 45 ±11
Compliance [mL/mbar] 26 ±15
Lung injury score (LIS) 3.4 ±0.4
ECMO therapy [%] 50
In-hospital mortality [%] 53.6
Simpliﬁed acute physiology score (SAPS) 63.5 ±13.6
Sepsis-related organ failure assessment (SOFA) 15.1 ±3.2
Means ± SD from 28 patients with ARDS. Data were obtained within 24
hours of admission.
T h ei m m u n o p r o t e a s o m ei sm o r el i k e l yt og e n e r a t ep e p -
tides with hydrophobic and basic C-terminal residues and
less likely to generate peptides with acidic C-terminal resi-
dues [12–14]. These short peptides (8–10 amino acids) are
subsequently translocated by the transporter associated with
antigen processing (TAP) to the endoplasmic reticulum
(ER), where a small part of them are loaded on major histo-
compatibility complex class-I molecules (MHC-I) and pre-
sented to cytotoxic T lymphocyte [15] on the cell membrane.
Concomitant with immunoproteasome synthesis induced
by IFN-γ, other components of the antigen presentation
machinery, like TAP [16] or the proteasome activator 28
(PA28), are also upregulated, and a decreased concentration
of standard intracellular 26S proteasome is observed [17].
While a prior paradigm was that the proteasome is loca-
ted only intracellularly, it is now accepted that proteasomes
can also be present extracellularly [10]. Recently, we have
reported the presence of biologically active 20S proteasome
intheextracellularalveolarspaceinhealthysubjects[18]and
in patients with the acute respiratory distress syndrome
(ARDS) [19]. Since ARDS goes along with pulmonary in-
ﬂammation [20], proinﬂammatory mediators [21, 22]l i k e
IFN-γ and TNF-α are produced, and the alveolar protea-
somal system could be altered. Accordingly, we investigated
whether alveolar proteasomal populations are changed in
lung inﬂammation and whether immunoproteasomes are
present in the alveolar space of ARDS patients.
2.MaterialandMethods
2.1. Patients and Clinical Procedures. Twenty-eight adult pa-
tients with severe ARDS (13 men, 15 women, mean age: 41
years ± 16 SD) were studied prospectively after approval of
the Ethics Committee of the University of Essen Medical
School. Characteristics of ARDS patients are depicted in
Table 1. To assess disease severity, lung injury score [23],
simpliﬁed acute physiology score (SAPS) [24], and sepsis-
relatedorganfailureassessment(SOFA)[25]w e r emeas ur ed.
Twenty-two patients (79%) had an ARDS of pulmonary ori-
gin, 50% underwent therapy with extracorporeal membrane
oxygenation (ECMO), and overall in-hospital mortality was
53.6%.
Patients were considered to suﬀer from ARDS and eli-
gible for BAL and blood sampling if they met the criteria
proposed by Bernard [20]: PaO2/fraction of inspired oxygen
(FIO2)r a t i oo f≤200mmHg while on a positive end-expi-
ratory pressure (PEEP) ≥10 cm H2O, bilateral radiographic
pulmonary inﬁltrates, and no clinical evidence of left atrial
hypertension or a pulmonary artery occlusion pressure of
18mmHgorless.Thebronchoalveolarlavage(BAL)wasper-
formed during sedation/anesthesia in the lung segment
showing radiological consolidation and inﬁltration.
Tenadultsubjectswithoutlungdisease(7men,3women,
mean age: 30 years ± 5) served as controls. They were free
of lung, cardiac, infectious, and allergic disease, had no his-
tory of chemotherapy or radiation therapy, and they were
nonsmokers. In these individuals, BAL and blood sampling
were performed during local anesthesia.
2.2. Bronchoalveolar Lavage (BAL). Within 24h of admis-
sion, ARDS patients underwent BAL [26, 27] for routine
workup of bacterial and viral infections. Four aliquots of
warm (37◦C) sterile isotonic saline (40mL) were instilled via
a bronchoscope wedged into a segmental bronchus and gen-
tly withdrawn. The BAL of healthy controls BAL was per-
formed by instilling saline into the right middle or left
lingular lob. A volume of greater than 50% was recovered,
ﬁltered through cotton gauze [28], and centrifuged (500g,
10min, 5◦C). The BAL supernatant was immediately frozen
using liquid nitrogen, stored at −80◦C ,a n ds e r v e da sa
sample of the extracellular alveolar ﬂuid.
In the pellet, cell counts were assessed by counting an ali-
quot in a Neubauer chamber [28]. For cell diﬀerentiation,
smears were air-dried and stained according to May-Gr¨ un-
wald-Giemsa[27].Theremainingcellpelletwasimmediately
frozen in liquid nitrogen and stored at −80◦C. After cell
lysis, the cell pellet was ultracentrifugated (30000g, 30min,
Beckman, M¨ unchen), and the upper portion of this centrifu-
gation step was used for further analysis.
2.3. Blood Samples. To detect immunoproteasome proteins,
if present, EDTA blood samples were drawn from all
ARDSpatientsandhealthycontrols.Bloodwascentrifugated
(500g, 10min, 5◦C) to separate the supernatant (plasma)
from cell pellet.
2.4. Measurements
2.4.1. SDS-PAGE Gelelectrophoresis. SDS-PAGE was per-
formed with Mini-Protean 3 Electrophoresis (Bio-Rad) with
15% gels according to [18]. 50μgp r o t e i np e rl a n ew e r ea p -
plied. The molecular weight standard was SeeBlue Pre-Stai-
ned Standard obtained from Invitrogen.
2.4.2. Detection of Immunoproteasome Proteins by Western
Blots. To detect the presence of proteasomal proteins sam-
ples (50μg per lane) from 28 ARDS patients and from 10
healthy subjects the samples were subjected to SDS/PAGE
andtransferredtoPVDF(BioRad)undersemidryconditions
withtheuseofaTrans-BlotSemi-DryElectrophoreticTrans-
fer Cell (BioRad). After blocking the PVDF membranes by
incubation with TBS-Tween buﬀer (5% Tween 20, 150mM
NaCl, 20mM Tris/HCl, pH 7.6) and StartingBlock BlockingMediators of Inﬂammation 3
Buﬀer (Pierce, Rockford) for 24 hours at 4◦C, the mem-
branes were incubated with rabbit polyclonal antibody to
20S proteasome subunit β1i (LMP2) (Biomol International
LP; PW 8840) (dilution 1:1000, 2h, room temperature),
rabbit polyclonal antibody to 20S proteasome subunit β5i
(LMP7) (dilution 1:2500, 2h, room temperature), and with
rabbit polyclonalantibodytoproteasomeactivator28(PA28)
(dilution 1:1000, 2h, room temperature), as described else-
where [29].
After washing with TBS-Tween buﬀer (5% Tween 20,
150mM NaCl, 20mM Tris/HCl, pH 7.6), the membranes
were incubated (1:10000, 1h, room temperature) with
peroxidase-conjugated aﬃnity-isolated goat anti-rabbit IgG
(Sigma Aldrich). After washing, the chemoluminescence
method was employed to detect the peroxidase activity using
an ECL kit (SuperSignal West Pico Chemiluminescence Sub-
strate, Pierce).
2.4.3. Determination of Total Proteasome Concentration in
BAL Supernatant. Proteasome concentration was measured
[30] by ELISA in BAL supernatants of all ARDS and of all
healthy subjects. Microtitration plates were coated overnight
withmousemonoclonalantibodyto20Sproteasomesubunit
α6 (HC2) (Biomol International L.P., Exeter, UK) 1:4500 in
PBS (Invitrogen GmbH, Karlsruhe, FRG), pH 7.4. The BAL
supernatants were diluted with an equal volume PBST-BSA
(PBS, Tween 20, 0.1%, and 1% bovine serum albumin) and
applied to each well for 3 hours at room temperature. All
measurements were covered by the linear portion of the res-
pective ELISA standard curve.
Standardcurveswereestablishedforeverymicrotitration
plate using 20S proteasome protein standards (Biomol Inter-
national L.P., Exeter, UK) of concentration ranging from
19.5ngmL−1 to 2500ngmL−1 (8 linear dilution steps). The
20S proteasome was diluted in PBS-T (PBS and Tween 20,
0.1%). The plates were washed once, and a rabbit poly-
clonal antibody (Biomol International L.P., Exeter, UK) to
20S proteasome (dilution 1:4000) was added for 2 hours
at room temperature. Following another four washing
steps peroxidase-conjugated mouse anti-rabbit IgG (Sigma-
Aldrich, Saint Louis, USA) was used for antigen detec-
tion (incubation period: 1h at room temperature). The
bound antibodies were detected using tetramethylbenzidine
(Sigma-Aldrich, Saint Louis, USA) as substrate. The reaction
was stopped with sulphuric acid, and OD-values were deter-
mined at 450nm. To exclude nonspeciﬁc binding, wells were
ﬁlled with bovine serum albumin (Sigma-Aldrich, Saint
Louis, USA), PBS, or PBS-T instead of BAL supernatant and
incubated with the antibody. No reaction was observed
under these control conditions.
2.4.4. Puriﬁcation of Proteasomes from BAL Supernatant. 20S
proteasomes from 5 patients with ARDS and from 5 healthy
subjects were puriﬁed as described elsewhere [31]. All puri-
ﬁcation steps were performed at 4◦C. To the pooled BAL
supernatant from 5 ARDS patients the same volume of
TEAD buﬀer (20mM Tris/HCl, 1mM EDTA, 1mM NaN3,
1mM DTT, pH 7.5) was added, and the mixture was homo-
genized by use of a Dounce homogenizer (20 strokes) under
ice cooling. Undissolved material was separated by centrifu-
gation (50min at 20000g). The supernatant was then sub-
jected to a column (1 × 8cm) of DEAE-Toyopearl 650S
(TOSOH Biosep GmbH, Stuttgart, Germany) equilibrated
with TEAD buﬀer. After washing the column with 50mM
NaCl/TEAD buﬀer, proteins bound to the resin were eluted
with a linear gradient of 50–500mM NaCl dissolved in
TEAD buﬀer. Fractions of 1mL were collected and tested
for their proteasome activity with the ﬂuorogenic substrate
Suc-LLVY-AMC. Proteasome-containing fractions were then
pooled, and 20S proteasomes were puriﬁed by successive
chromatographies on Superose 6 (Pharmacia HR 10 × 30),
Mono Q (HR 5/5) and Phenyl-Superose (HR 5/5) in con-
junction with the FPLC system. All chromatographies were
r u ni nT E A Db u ﬀer. For elution of the enzyme from MonoQ
a gradient of 0–500mM NaCl and from Phenyl-Superose a
gradient of 1.2–0M (NH4)2SO4 were used, respectively. The
puriﬁed enzyme was ﬁnally dialyzed against TEAD buﬀer.
2.4.5. Puriﬁcation of Proteasomes from Human Spleen, Cells,
and Plasma. Puriﬁcation of proteasomes from human ery-
throcytes and plasma was performed exactly as described by
Zoegeretal.[32].Brieﬂy,“fractionII”waspreparedfromcell
extract by use of DEAE-Sephacel, which was then used
to obtain by ammonium sulphate (30–80% saturated with
(NH4)2SO4)precipitationaproteasome-containingfraction.
The enzyme was then puriﬁed by successive chromatography
on DEAE-Toyopearl 650S, preparative Superose 6, and
MonoQ. For all chromatographic TEAD buﬀer was used.
Finally,theenzymewassubjectedtoaﬃnitychromatography
with an antibody to subunit α3 as ligand, as described else-
where [32], and was then dialysed against TEAD buﬀer.
Normal human spleen tissue purchased from Enzo Life
sciences Ltd.
2.4.6. Two-Dimensional Polyacrylamidegel Electrophoresis
(2D-PAGE). Preparation and performing 2D-PAGE with
puriﬁed proteasomes from BAL supernatant of ARDS pa-
tients in 8 × 10cm gels were exactly done as described by
Schmidt et al. [33]. Designation of proteasome subunits cor-
respondedtothatusedbySchmidtetal.[33]andb yF r oment
et al. [34] without applying the nomenclature of the minor
subforms of the α-a n dβ-subunits. Proteasome concentra-
tionofhealthysubjectsafterpuriﬁcationwastoolowtoallow
additional 2-D PAGE electrophoresis.
2.4.7. Proteasomal Activity. The proteasomal activity was
measured ﬂuorometrically in BAL supernatant in all ARDS
patients and in all healthy controls using speciﬁc ﬂuorogenic
substrates and techniques previously described (19). We
tested for peptidyl-glutamyl peptide-hydrolysing activity
(PGPH) with 200μM benzoyloxycarbonyl-LLE-7-amido-
4-methylcoumarin (Z-LLE-MCA), for trypsin-like activity
(Try)with200μMbenzoyl-VGR-MCA(Bz-VGR-MCA),and
for chymotrypsin-like activity (Chtr) with 100μMs u c c i n y l -
LLVY-MCA (Suc-LLVY-MCA) as substrates (46, 47). All
measurements were performed in duplicate and averaged
for each subject. To describe the speciﬁc enzyme activity of4 Mediators of Inﬂammation
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Figure 1: Western blots with a polyclonal antibody directed against
LMP2 or LMP7 subunits of the immunoproteasome of samples of
BAL supernatant and BAL cell pellet lysate obtained from ARDS
patients. (a) LMP2 immunoproteasome protein was detected in
both BAL supernatant and cell pellet in all ARDS patients. Lanes
are identiﬁed as follows: Lane 1: 1μg immunoproteasome (human
spleen); Lane 2: cell pellet ARDS patients 1; Lane 3: BAL super-
natant ARDS patients 1; Lane 4: cell pellet ARDS patients 2; Lane
5: BAL supernatant ARDS patients 2; Lane 6: cell pellet ARDS
patients 3; Lane 7: BAL supernatant ARDS patients 3; Lane 8: cell
pellet ARDS patients 4; Lane 9: BAL supernatant ARDS patients 4.
(b) LMP7 immunoproteasome protein was detected in both BAL
supernatantandcellpelletinallARDSpatients.Lanesareidentiﬁed
as follows: Lane 1: 1μg immunoproteasome (human spleen); Lane
2: 1μg 20S standard proteasome (human erythrocyte); Lane 3: cell
pellet ARDS patients 1; Lane 4: BAL supernatant ARDS patients 1;
Lane 5: cell pellet ARDS patients 2; Lane 6: BAL supernatant ARDS
patients2;Lane7:cellpelletARDSpatients3;Lane8:BALsuperna-
tant ARDS patients 3.
extracellular proteasomes we used ﬂuorogenic substrate
cleavage (pmol/min ×μg).
2.4.8. Analysis of Proteasome Subtypes. Puriﬁed 20S prote-
asomes from 5 pooled BAL supernatants of ARDS patients
were separated by high-resolution anion exchange chroma-
tography (in conjunction with a SMART-Chromatography
System;AmershamBiosciences)onMiniQequilibratedwith
TEAD-buﬀer exactly as described elsewhere [35]. Puriﬁca-
tion of 20S proteasome from pooled BAL of 5 healthy sub-
jects turned out to be impossible due to the low 20S protea-
some concentration in BAL supernatant.
2.4.9. Lactate Dehydrogenase Activity in BAL Supernatant.
Total (LDH1–LDH5) lactate dehydrogenase (LDH) activity
was measured by a kinetic uv-test (Diaglobal GmbH, Berlin,
FRG) using an optimized standard method (IFCC).
2.4.10. Total Protein Concentrations in BAL Supernatant.
Total protein concentration was determined after trichloro-
acetic acid (TCA) precipitation (5%), washing, and resolubi-
lization according to Lowry using an autoanalyzer (Techni-
con) employing bovine serum albumin (BSA) as a standard.
2.5. Chemicals. All chemicals were of highest available or
analytical grade. Water was deionized, distilled, and passed
through a Milli-Q-System (Millipore, Witten) before use.
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Figure 2: Representative western blots with a polyclonal antibody
directed against LMP2 or LMP7 subunits of the immunopro-
teasome of samples of BAL supernatant obtained from healthy
subjects. (a) LMP2 immunoproteasome protein could not be detec-
ted in BAL supernatant of any healthy subject. Lanes are identiﬁed
as follows: Lane 1: 1μg 20S standard proteasome (human erythro-
cyte); Lane 2: 1μg immunoproteasome (human spleen); Lane 3:
BALsupernatanthealthysubject1;Lane4:BALsupernatanthealthy
subject 2; Lane 5: BAL supernatant healthy subject 3; Lane 6: BAL
supernatant healthy subject 4; Lane 7: BAL supernatant healthy
subject 5; Lane 8: BAL supernatant healthy subject 6; Lane 9: BAL
supernatant healthy subject 7. (b) LMP7 immunoproteasome pro-
tein could not be detected in BAL supernatant of any healthy
subject. Lanes are identiﬁed as follows. Lane 1: 1μg 20S standard
proteasome (human erythrocyte); Lane 2: 1μg immunoproteasome
(human spleen); Lane 3: BAL supernatant healthy subject 1; Lane 4:
BALsupernatanthealthysubject2;Lane5:BALsupernatanthealthy
subject 3; Lane 6: BAL supernatant healthy subject 4; Lane 7: BAL
supernatanthealthysubject5;Lane8:BALsupernatanthealthysub-
ject 6; Lane 9: BAL supernatant healthy subject 7.
2.6. Statistical Analysis. Analyses were performed with SPSS,
version 9 (SPSS, Inc., Chicago, USA). Continuous variables
arepresentedasmeans ±standarddeviation(SD).Nonpara-
metric variables were compared by using the Mann-Whitney
U-test, as indicated. Data are presented as median and range
and were not normally distributed. Comparison of values of
variablesbetweengroups(ARDSversushealthysubjects)was
performed using the Mann-Whitney U test. Diﬀerences were
regarded as statistically signiﬁcant with an a priori alpha-
error P of less than 0.05.
3. Results
Most important, all ARDS patients showed both LMP2 and
LMP7 immunoproteasome proteins in the BAL supernatant
and also in their cell pellet lysate (Figures 1(a) and 1(b)). In
contrast, LMP7 and LMP2 were not detected in the BAL
supernatant (Figures 2(a) and 2(b)) of any healthy subject.
LMP2 was only detected in the cell pellet of healthy controls
whereas LMP7 was not.
The molecular weight of the immunoproteasome posi-
tive protein bands in the western blots of the BAL cell pellet
lysate from ARDS patients was greater than that in their BAL
supernatants, suggesting that extracellular immunoprotea-
some protein-containing proteasomes are assembled from
larger intracellular pro-proteins.Mediators of Inﬂammation 5
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Figure 3: Representative Western blot with a polyclonal antibody
directed against PA28 in BAL supernatant of twelve patients with
ARDS. PA28 protein could not be detected in the BAL supernatant
ofARDSpatients.Startandfrontofthegelweremarkedas+and −.
Lanes are identiﬁed as follows: Lane 1: 1μg PA28 (standard); Lane
2–13 BAL supernatant of twelve ARDS patients.
PA28couldneitherbedetectedinBALsupernatantsofall
patients with ARDS nor in healthy controls. Figure 3 shows
a western blot with an antibody directed against the PA28
activator.
Puriﬁcationand2-DgelelectrophoresisoftheBALsuper-
natant from ARDS patients showed 20S proteasomal core
proteins (Figure 4(a)). Immunoproteasome subunits β1i
(LMP2), β2i (MECL-1), and β5i (LMP7) were detected
in the two-dimensional polyacrylamide gelelectrophoresis
(Figure 4) conﬁrming the data derived from the western
blots. Like BAL supernatant from ARDS patients samples of
splenictissue,butnothumanredcells,revealedimmunopro-
teasome subunits.
Comparison of the speciﬁc activities of puriﬁed pro-
teasome (Table 2) from pooled BAL supernatant of healthy
controls and of ARDS patients showed a lower proteasomal
activityinARDSpatientsbutalsoadiﬀerentratiooftheindi-
vidual proteasomal enzyme activities (Table 2) suggesting a
change of proteasomal subunit composition. With a ratio
of peptidyl-glutamyl peptide-hydrolysing activity (PGPH)
to trypsin-like activity (Try) of 11.2 versus 14.6, a ratio of
chymotrypsin-like activity (Chtr) to trypsin-like activity of
33 versus 14.5, and a ratio of the chymotrypsin-like activity
to the peptidyl-glutamyl peptide-hydrolysing activity (Chtr/
PGPH:2.95versus0.99)theseactivityratioswerediﬀerentin
ARDS patients when compared to healthy controls.
Chromatography (Figure 5)o fap o o l e ds a m p l eo fB A L
supernatants from 5 ARDS patients revealed a new proteaso-
mal subtype pattern with distinct numbers and proportions
of seven peaks (I–VII) unlike that of human circulating
plasma proteasome. In fact, since the alveolar subtype pat-
tern seen in ARDS patients was not even similar to the
subtypepatternsfoundinerythrocytes,platelets,monocytes,
and T lymphocytes (32), respectively, the extracellular alveo-
lar proteasome found in ARDS patients is unlikely to derive
from the blood stream.
IncontrasttotheBALsupernatantofhealthyindividuals,
the plasma and the BAL cell pellet of all healthy subjects and
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Figure 4: 2D-PAGE of puriﬁed 20S proteasomes from (a) red cells
(5μg), (b) BAL-supernatant (20μg) from ARDS patients, and (c)
spleen (30μg). Detection of protein spots was performed by silver
staining and Coomassie BB G250, respectively. Standard 20S pro-
teasome was exclusively detected in red cells (a). Samples of human
spleen and of the BAL supernatants from ARDS patients showed
both standard and immunoproteasome proteins (panels (b) and
(c)).
of all ARDS patients showed both LMP2 and LMP7 proteins
in the western blots (data not shown).
Total proteasome concentration in BAL supernatants of
ARDS patients was higher (971 ± 1116ng/mL) compared to
healthy subjects (59 ± 25; P<0.001) (Table 3), and all ﬂu-
orogenic substrates were hydrolyzed by BAL supernatants of
ARDSpatients(Suc-LLVY-AMC:3.1±6.2pkat/mg;Bz-VGR-
AMC: 1.8 ± 2.5; Z-LLE-AMC: 0.8 ± 1.1) and of healthy
subjects (Suc-LLVY-AMC: 7.3±3.7pkat/mg; Bz-VGR-AMC:
5.6 ± 3.2; Z-LLE-AMC: 2 ± 1.2), with inhibition by epoxo-
micin (P = 0.0001).
There was no signiﬁcant correlation (P = 0.16) in ARDS
patients between proteasome concentration in BAL super-
natant and in their plasma. In addition, there was no correla-
tion between LDH activity and proteasome concentration in
BAL supernatant (P = 0.21), or between BAL cell count and
proteasome concentration in BAL supernatant (P = 0.26),
ruling out cell lysis as a major source of proteasome in the
extracellular alveolar space.
Our patients by any criteria had severe ARDS (Table 1)
and also showed marked physiological derangements, as
indicated by a high simpliﬁed acute physiology score and
sepsis-related organ failure assessment.6 Mediators of Inﬂammation
Table 2: Speciﬁc activities of proteasomes isolated from healthy controls and ARDS patients.
Chtr (pmol/min μg) Try (pmol/min μg) PGPH (pmol/min μg) Chtr/PGPH PGPH/Try Chtr/Try
Healthy controls 24.31 0.73 8.22 2.95 11.2 33.3
ARDS patients 9.87 0.68 9.93 0.99 14.6 14.5
Proteolytic activities of puriﬁed 20S proteasome from BAL supernatant of healthy controls and of ARDS patients, as measured with speciﬁc proteasomal
ﬂuorogenic substrates. BAL supernatants were pooled from 5 healthy subjects and from 5 ARDS patients, respectively. The ratio of enzyme activities diﬀers
between ARDS patients and healthy subjects, suggesting a rearrangement of proteasomal subunit composition.
PGPH: peptidyl-glutamyl peptide-hydrolysing activity; Try: trypsin-like activity; Chtr: chymotrypsin-like activity.
Table 3: Characteristics of BAL in ARDS and healthy subjects.
ARDS patients (n = 28) Healthy subjects (n = 10) P value
Proteasome concentration in BAL supernatant [ng/mL] 971 ± 1116 59 ± 25 <0.001
Proteasome concentration in plasma [ng/mL] 2855 ± 2422 348 ± 126 <0.001
Suc-LLVY-AMC proteasome activity in BAL supernatant [pkat/mg] 3.1 ±6.27 .3 ±3.7 <0.001
BZ-VGR-AMC proteasome activity in BAL supernatant [pkat/mg] 1.8 ±2.55 .7 ±3.2 <0.001
Suc-LLE-AMC proteasome activity in BAL supernatant [pkat/mg] 0.8 ±1.12 ± 1.2 0.002
Total protein concentration in BAL supernatant [mg/mL] 3.8 ±6.40 .06 ±0.01 <0.001
Albumin concentration in BAL supernatant [mg/mL] 1.5 ± 30 .03 ±0.01 0.0011
LDH in BAL supernatant [U/L] 342 ± 779 28 ± 9.7 0.024
LDH in plasma [U/L] 821 ± 1104 184 ± 53 <0.001
Cell count in cell pellet [106/mL] 330 ± 994 8.6 ±2.5 0.007
Macrophages [%] 29.1 ±27.49 2 .6 ±3.4 <0.001
Neutrophile granulocytes [%] 65.1 ±27.72 .8 ±2.5 <0.001
Lymphocytes [%] 5.1 ±7.96 .3 ±2.9 0.056
Data are means ± SD.
4. Discussion
Our data show that the extracellular alveolar space in ARDS
patients contains (1) an altered proteasomal composition
with a distinct proteasomal subtype pattern, and (2) immu-
noproteasome proteins, that is, a diﬀerent type of protea-
some when compared to healthy subjects. Most likely, these
alterations are evoked by pulmonary inﬂammation.
Intracellularly, three subpopulations of 20S proteasomes
are known, that is, standard proteasome, immunoprotea-
some, and intermediate-type proteasomes. These subpop-
ulations can only be separated and characterized by high-
resolution anion exchange chromatography, as used in our
study, and not by ELISA or western blotting techniques.
Detection of the immunoproteasomal subunits LMP 2
and LMP 7 in the extracellular alveolar space in all ARDS
patients but not in healthy controls was associated with
a change in the ratio of proteasomal enzyme activities as
revealed following puriﬁcation. This is consistent with
reportsthatintermediate-typeproteasomesorimmunoprot-
easomes, at least in cell cultures, show an altered ratio of
peptidyl-glutamyl peptide-hydrolyzing to trypsin-like activ-
ity and of chymotrypsin-like to trypsin-like activity when
compared to the standard 20S proteasome [11, 13, 14, 36,
37]. Presumably, this is caused by a decrease in size and
charge of the S1 pocket of βi1 as compared to that of β1 [38].
Thus, the observed change of proteasomal composition and
activity in BAL supernatant of ARDS patients may be caused
by replacement of standard 20S proteasome proteins by
catalyticsubunitsβ1i (LMP2),β2i (MECL-1),andβ5i (LMP7)
that are incorporated into a newly synthesized intermediate
type and/or immunoproteasome.
Despite detection of immunoproteasome proteins LMP
2 and LMP 7 by western blot and of MECL-1 by 2-D gele-
lectrophoresisitremainsunclearwhetheritispureimmuno-
proteasome and/or intermediate-type proteasomes that are
found in the extracellular alveolar space of ARDS patients.
However, data obtained in cells [32] suggest that the protea-
somal subtype pattern seen in BAL supernatant of our ARDS
patients represents intermediate-type proteasome as a dom-
inant proteasome fraction. The higher molecular weight of
the Immuno β catalytic subunits in the cell pellet lysate of
ARDS patients presumed the existence of proproteins as des-
cribed elsewhere [39–41]. These ﬁndings suggest that the
Immuno β catalytic subunits were built in the cell pellet, and
the completed immunoproteasomes were transported into
the alveolar space. This mechanism of extracellular transport
of the immunoproteasome is unclear and further work had
to be done to clarify this question.
In any case, that immunoproteasome proteins were
detected in the BAL supernatant of ARDS patients but not
in healthy individuals, which likely represents a biological
reaction in response to alveolar inﬂammation. ARDS results
in a marked proinﬂammatory response with high IFN-γ and
TNF-α[21,42,43]concentrationinthealveolarspace.While
we did not measure alveolar cytokine concentrations one
may speculate that high IFN-γ concentrations induce the
assembly of immunoproteasome proteins. In this context,Mediators of Inﬂammation 7
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Figure 5: Subtype pattern of the extracellular alveolar proteasome
of patients with ARDS (continuous line) and of plasma from
healthy subjects (white points). (a) 20μg of 20S proteasome from
pooled BAL supernatant of ﬁve ARDS patients were puriﬁed,
subjected to chromatography on Mini Q, and separated into their
subtypes by elution with increasing concentrations of NaCl. Sub-
types detected by absorption at 280nm are designated by roman
ﬁgures (I–VII) according to the order of their elution from the
column. All subtypes elute at NaCl concentrations (dashed line)
between 330 and 370 mmolNaCl/L, and only this detail of the chro-
matograms is shown. (b) All collected fractions of the subtype pat-
ternchromatographyoftheextracellular alveolarproteasomeofpa-
tients with ARDS were measured by the highly speciﬁc proteasomal
ﬂuorogenic peptides Suc-LLVY-AMC (open points), BZ-VGR-
AMC (black rectangle), and Suc-LLE-AMC (Z-LLE-AMC) (open
triangle). Only in the fractions 28–30, proteasomal enzyme activity
could be observed. Analysis of alveolar proteasome revealed a new
proteasomal subtype pattern in the extracellular alveolar space of
ARDS patients that diﬀers from that of healthy subjects’ plasma,
suggesting that the extracellular alveolar proteasome in ARDS does
not derive from plasma.
the greater molecular weight of the immuno β catalytic sub-
units found in the cell pellet lysate of ARDS patients suggests
the existence of immunoproteasome pro-proteins (13–15)
that by a yet undeﬁned mechanism apparently gain access to
the extracellular space.
In this study, we identiﬁed for the ﬁrst time a new pro-
teasomal subtype pattern in the alveolar space of ARDS pa-
tients that diﬀers from that of proteasomes in blood cells.
Therefore, the extracellular alveolar immunoproteasome
and/or intermediate-type proteasome found in ARDS pa-
tients is unlikely to derive from cytolysis of blood cells and
sequestrationoftheir contentsinto alveoli acrossleakyendo-
thelial and epithelial barriers. This is supported by the ﬁnd-
ing that no signiﬁcant correlation between the proteasome
concentration in plasma and in BAL supernatant was seen.
Thus, while endothelial and epithelial damage as well as
basement membrane destruction is a feature of ARDS [20,
44] extravasation of circulating proteasomes alone cannot
be responsible for the presence of extracellular alveolar 20S
proteasomes.
By the same token, it is unlikely that alteration of pro-
teasomal composition in the alveolar space in ARDS patients
resultedfromlysisofcellsofthealveolarwall.Thisappearsto
beruledoutbythefactthatPA28proteasomalcaps,normally
present intracellularly, were not found in western blots
from BAL supernatant of patients with ARDS. In addition,
masked PA28 proteasomal caps (by proteins or protein com-
plexes) might not be accessible using western blot analysis
so that this conclusion has to be veriﬁed by MS analysis.
Furthermore, no signiﬁcant correlation between total pro-
teasomal concentration in BAL supernatant and LDH activ-
ity, a marker of cell lysis, or with the BAL cell count was ob-
served. Thus, the presence of immunoproteasome proteins
likelyrelatestotheinﬂammatoryprocessinlungtissuerather
than to cell lysis.
Since no 19S and PA28 proteasomal cap proteins were
detectedbywesternblotofBALsupernatant,26Sproteasome
and/or hybrid proteasome were not present in the alveolar
space of patients with ARDS. However, since the detection
limit of our method is in the range of 0.5–1μg protein/μLw e
cannot excludethe presenceof lesserextracellularconcentra-
tions of 26S proteasome.
Our data showing the presence of immunoproteasome
proteins and a distinct proteasomal subtype pattern in BAL
supernatant from patients with ARDS extend our previous
work [19] reporting increased total proteasome concentra-
tions but lesser proteasomal activities when compared to
healthy subjects.
Diﬀerent types of proteasomes are known to have diﬀer-
ent cleavage repertoires [45]a n dt oy i e l dd i ﬀerent peptides
for antigen presentation [16]. Possibly, a function of the
extracellular immunoproteasome, evoked by inﬂammation,
could be to cleave epitopes diﬀerent from that of the stan-
dard 20S proteasome. It is unknown which extracellular pro-
teins are degraded by the standard proteasome and which
ones by the immunoproteasome or the intermediate-type
proteasome. However, the presence of immunoproteasome
proteins may suggest an altered extracellular protein degra-
dation [26]. In any case, the presence of immunoproteasome
proteins in the BAL supernatant of ARDS patients raises the
provocative question whether antigen processing and hence8 Mediators of Inﬂammation
part of the immunological response could also take place in
the extracellular alveolar space.
To our knowledge, this study is the ﬁrst to address the
presence of immunoproteasome proteins in lung disease and
the activity of extracellular alveolar proteasome in ARDS
patients. Fluorogenic substrates, used in combination with
epoxomicin, the most potent, selective, and irreversible pro-
teasome inhibitor currently available, and an ELISA are
accepted methods for analyzing proteasomal existence and
activity [30, 46, 47]. In this study, we used an ELISA tech-
nique for the measurement of proteasomal concentration in
the BAL supernatant. This technique does not allow to
discriminate quantitatively between the 20S proteasome and
the immunoproteasome. The western blots directed against
LMP2 and LMP7, however, showed high signal intensity
of the immunoproteasome proteins, likely reﬂecting a high
concentration of immunoproteasome proteins in the BAL
supernatant, in patients with ARDS but not in healthy con-
trols.
It is conceivable, therefore, that quantitative immuno-
proteasome measurements in BAL might provide discrim-
ination between disease activity, clinical scores, predictable
survival, and eﬃcacy of therapy. Obviously, this should be
addressed in further studies.
In summary, we identiﬁed immunoproteasome proteins
in the extracellular alveolar space of patients with ARDS,
whichareabsentinhealthycontrols,andwediscoveredadis-
tinct, previously undescribed alveolar proteasome subtype
pattern that diﬀers from the 20S proteasomes found in
various blood cells. This may alter cleavage of alveolar pro-
teins existing in the alveolar space during pulmonary inﬂam-
mation seen in ARDS.
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